Liquidia Corporation

Latest Report Overview

Liquidia Corp (LQDA) reported For the quarterly period ended June 30, 2026 (Issuer fiscal Q2 FY2026) revenue of $172 million with diluted EPS of $0.74 and net income of $74.7 million. Operating margin was 49.8%, and free cash flow was $68 million for the period. The strong financial performance in Q2 2026 highlights the successful commercial uptake of YUTREPIA following its regulatory progress. The company achieved profitability during the period, supported by robust product demand and high gross margins, reflecting the scalability of their proprietary PRINT® technology platform. Management continues to focus on market penetration in the PH-ILD and PAH segments. Operational efforts remain concentrated on sustaining this growth trajectory while navigating the complex regulatory and patent landscape. The company's focus remains on expanding its commercial footprint and leveraging its technology to secure and maintain market share against established competitors in the pulmonary hypertension therapeutic space.

Key Takeaways for Liquidia Corp

• Liquidia achieved a significant inflection to profitability in Q2 2026, reporting net income of $74.7 million and diluted EPS of $0.74.
• Revenue growth remains explosive, with Q2 2026 revenue of $171.7 million representing an ~1843% increase YoY.
• The primary commercial driver is the rapid market uptake of YUTREPIA, validated by strong margins (93.3% gross margin).
• Legal and patent litigation regarding treprostinil-based therapies, particularly with United Therapeutics, remains an existential threat to market stability.
• The company maintains a healthy liquidity position with $284.2 million in cash against $176.1 million in debt, supporting ongoing commercial operations.

What Does Liquidia Corp Do?

Liquidia Corp is a biopharmaceutical company focused on the development and commercialization of innovative products to address the needs of patients with pulmonary hypertension (PH). The company utilizes its proprietary PRINT® technology, a particle engineering platform, to create inhaled formulations that are designed to be precise, uniform, and suitable for the delivery of potent drugs. Its flagship product, YUTREPIA, is an inhaled treprostinil intended for the treatment of PH-ILD and PAH. The company operates within the specialty pharmaceutical market, specifically targeting the pulmonary hypertension vertical in the United States. With a market-ready product and a growing commercial infrastructure, the company has successfully transitioned to a revenue-generating entity, focusing on patient access and provider adoption of their therapeutic solutions.

Growth Drivers for Liquidia Corp

• Market penetration of YUTREPIA in the PH-ILD and PAH treatment indications.
• Adoption rates by pulmonologists and specialized treatment centers.
• Successful navigation of the complex regulatory and payer reimbursement environment.
• Utilization of the proprietary PRINT® platform to potentially develop future inhaled therapeutics.
• Expansion of sales and commercial infrastructure to capture remaining market opportunities.